ArticleNeuropsychopharmacology reports2026
Real-World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database.
Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimVortioxetine has been approved for the treatment of patients with major depressive disorder (MDD) in Japan since 2019; however, limited data are available on its use in clinical practice. This study aimed to identify real-world prescribing patterns for first-line antidepressant treatment of patients with MDD in Japan, and to understand how patient characteristics influence treatment selection and continuation.
methodsThis retrospective cohort study utilized data from the JMDC claims database. Patients with MDD (aged ≥ 18 years) were included if they were newly prescribed antidepressants between November 1, 2019 and May 31, 2024. The primary outcome was the distribution of antidepressants prescribed as first-line treatment. Secondary outcomes included evaluating treatment patterns and characteristics among patients receiving a single antidepressant as first-line therapy.
resultsThe analysis population included 263 773 patients, of whom 97.4% had single-drug prescriptions (vortioxetine [10.2%], selective serotonin reuptake inhibitors [48.3%], serotonin-norepinephrine reuptake inhibitors [15.2%], noradrenergic and specific serotonergic antidepressants [9.8%], and other antidepressants [13.9%]), and 2.6% had multiple-drug prescriptions. Patients were less likely to be prescribed vortioxetine if they were female (odds ratio: 0.802; 95% confidence interval: 0.781-0.824) or older than 60 years (0.544; 0.498-0.594), whereas patients with somnolence (2.248; 1.152-4.385), adjustment disorders (1.488; 1.433-1.544), and nausea and vomiting (1.253; 1.194-1.315) were more likely to be prescribed vortioxetine. In the first 3 months after initiating vortioxetine treatment, 41.3% of patients continued treatment, 44.7% discontinued, and 14.0% changed treatment. Treatment change was more common in women (1.129; 1.046-1.218), and in patients with physical symptoms, whereas mental health-related comorbidities were associated with treatment persistence.
conclusionThese findings suggest that vortioxetine is more commonly prescribed to working-age men in Japan, and that patient characteristics and tolerability considerations contribute to prescribing and continuation patterns in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.